TAK-715 Clinical Trials

Size	Price	Qty
10mg	USD 147

Clinical Trials

The clinical development landscape for TAK-715 includes a clinical trial evaluating its therapeutic utility in inflammatory disorders, specifically rheumatoid arthritis. Sponsored by Takeda, this completed Phase 2 study utilized a randomized, double-blind, placebo-controlled, dose-ranging design to evaluate the safety, tolerability, and efficacy of oral dosing regimens.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00760864	COMPLETED	Arthritis, Rheumatoid	Takeda	2004-08	PHASE2

(data from https://clinicaltrials.gov, updated on 2010-06-11)

Check the TAK-715 product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

TAK-715 selectively binds to and inhibits p38α mitogen-activated protein kinase, blocking downstream signaling cascades and suppressing the intracellular production of pro-inflammatory cytokines. By inhibiting p38α-dependent inflammatory signaling and cellular responses, the compound reduces tissue inflammation and structural degradation, supporting its clinical evaluation for the treatment of rheumatoid arthritis.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).